CSPC OUYI PHARMACEUTICAL CO., LTD.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-03-29
- Employees
- -
- Market Cap
- -
- Website
- http://www.e-cspc.com
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
Phase 3
Recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Dextromethorphan and Bupropion Sustained-Release TabletsDrug: Placebo
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 388
- Registration Number
- NCT06958692
- Locations
- 🇨🇳
Beijing Anding Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT06943950
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT06571461
A Phase II Study of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06562894
A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06511739
- Locations
- 🇨🇳
Clinical Trials Information Group, Shijiazhuang, China
Safety and Efficacy Study of Pilocarpine HCl Ophthalmic Solution in Participants With Presbyopia
Phase 3
Not yet recruiting
- Conditions
- Presbyopia
- Interventions
- Drug: Vehicle
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT06451666
A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
Phase 3
Not yet recruiting
- Conditions
- Painful Diabetic Neuropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 358
- Registration Number
- NCT06383702
Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06360445
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06354114
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT05858047
- Locations
- 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath